BR9703546A - Modulação da função receptora lc 132 (tipo opióide) - Google Patents

Modulação da função receptora lc 132 (tipo opióide)

Info

Publication number
BR9703546A
BR9703546A BR9703546A BR9703546A BR9703546A BR 9703546 A BR9703546 A BR 9703546A BR 9703546 A BR9703546 A BR 9703546A BR 9703546 A BR9703546 A BR 9703546A BR 9703546 A BR9703546 A BR 9703546A
Authority
BR
Brazil
Prior art keywords
modulation
receptor function
opioid type
opioid
type
Prior art date
Application number
BR9703546A
Other languages
English (en)
Inventor
Hans Peter Nothacker
Jean Luc Moreau
Rainer Reinscheid
Oliver Civelli
James Richard Martin
Frederick Monsma
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR9703546A publication Critical patent/BR9703546A/pt

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9486Analgesics, e.g. opiates, aspirine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR9703546A 1996-06-13 1997-06-13 Modulação da função receptora lc 132 (tipo opióide) BR9703546A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96109462 1996-06-13

Publications (1)

Publication Number Publication Date
BR9703546A true BR9703546A (pt) 1998-09-29

Family

ID=8222893

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9703546A BR9703546A (pt) 1996-06-13 1997-06-13 Modulação da função receptora lc 132 (tipo opióide)

Country Status (17)

Country Link
US (2) US6326156B1 (pt)
JP (1) JP3212537B2 (pt)
KR (1) KR100247670B1 (pt)
CN (1) CN1184254A (pt)
AR (1) AR007548A1 (pt)
AU (1) AU719519B2 (pt)
BR (1) BR9703546A (pt)
CA (1) CA2206192A1 (pt)
CZ (1) CZ179597A3 (pt)
HU (1) HUP9701032A3 (pt)
IL (1) IL121017A0 (pt)
MX (1) MX9704352A (pt)
NO (1) NO972707L (pt)
NZ (1) NZ328033A (pt)
PL (1) PL320527A1 (pt)
TR (1) TR199700482A2 (pt)
ZA (1) ZA975077B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA80841C2 (en) * 2002-10-07 2007-11-12 Univ California Fatty acid amide hydrolase inhibitors, pharmaceutical composition (variants) and method to treat appetite disorders, glaucoma, pain, and related neurological disorders (variants)
WO2008030752A2 (en) * 2006-09-07 2008-03-13 N.V. Organon Methods for determining effective doses of fatty acid amide hydrolase inhibitors in vivo
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
EP2096915A1 (en) * 2006-11-20 2009-09-09 N.V. Organon Metabolically-stabilized inhibitors of fatty acid amide hydrolase
AU2009233711B2 (en) 2008-04-09 2015-02-12 Infinity Pharmaceuticals, Inc Inhibitors of fatty acid amide hydrolase
CA2757679A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
WO2010118159A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
US8927551B2 (en) * 2009-05-18 2015-01-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US8765735B2 (en) * 2009-05-18 2014-07-01 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US9149465B2 (en) * 2009-05-18 2015-10-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
WO2011097233A1 (en) * 2010-02-03 2011-08-11 Infinity Pharmaceuticals, Inc. Fatty acid amide hydrolase inhibitors
JP5981429B2 (ja) 2010-07-28 2016-08-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 末梢に制限されたfaah阻害剤
JP6092870B2 (ja) 2011-08-19 2017-03-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア メタ置換ビフェニル末梢に限局されたfaah阻害剤
US9630979B2 (en) 2011-09-29 2017-04-25 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
EP3988540A1 (en) 2014-04-07 2022-04-27 The Regents of the University of California Inhibitors of fatty acid amide hydrolase (faah) enzyme with improved oral bioavailability and their use as medicaments
CN114796446B (zh) * 2021-01-22 2024-08-30 宁夏杞肽科技有限公司 孤啡肽治疗氯胺酮成瘾的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5316759A (en) * 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
DE3718317A1 (de) 1986-12-10 1988-06-16 Bayer Ag Substituierte basische 2-aminotetraline
EP0612845A3 (en) 1993-02-26 1994-09-21 American Cyanamid Co Purified opioid receptor.
US6096513A (en) 1993-05-20 2000-08-01 Arch Development Corporation Polynucleotides encoding KAPPA opiod receptors
US5658783A (en) * 1993-11-08 1997-08-19 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non-Profit Organization Mammalian methadone-specific opioid receptor gene and uses
US5476933A (en) * 1994-11-16 1995-12-19 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Azepine synthesis via a diels-alder reaction
US5821219A (en) 1995-08-11 1998-10-13 Oregon Health Sciences University Opioid antagonists and methods of their use
EP1241259A1 (en) 1995-08-15 2002-09-18 Universite Libre De Bruxelles Peptide having pronociceptive properties

Also Published As

Publication number Publication date
NO972707L (no) 1997-12-15
HU9701032D0 (en) 1997-07-28
US6326156B1 (en) 2001-12-04
US20020082213A1 (en) 2002-06-27
PL320527A1 (en) 1997-12-22
HUP9701032A3 (en) 2000-04-28
MX9704352A (es) 1997-12-31
NZ328033A (en) 1998-11-25
AR007548A1 (es) 1999-11-10
ZA975077B (en) 1997-12-15
AU2485397A (en) 1997-12-18
CZ179597A3 (cs) 1998-03-18
JP3212537B2 (ja) 2001-09-25
TR199700482A2 (xx) 1998-01-21
KR100247670B1 (ko) 2000-06-01
IL121017A0 (en) 1997-11-20
NO972707D0 (no) 1997-06-12
CN1184254A (zh) 1998-06-10
CA2206192A1 (en) 1997-12-13
HUP9701032A2 (hu) 1998-08-28
AU719519B2 (en) 2000-05-11
KR980003586A (ko) 1998-03-30
JPH1068724A (ja) 1998-03-10

Similar Documents

Publication Publication Date Title
DE69700139D1 (de) Nanopigmente-enthaltende kosmetische Zusammensetzungen
FI944969A (fi) Indolijohdannaisia
DE59706144D1 (de) Ausrichtvorrichtung
NO991647L (no) Ledekile
DE69734005D1 (de) Gelenkmechanismus
SE0000755A0 (sv) Gångjärnsförsett spärrelement
NO996108D0 (no) 9-oksinerytromycinderivater
DE69718276D1 (de) Fixiergerät
DK0963621T3 (da) Strømskinne
BR9703546A (pt) Modulação da função receptora lc 132 (tipo opióide)
ID19801A (id) Turunan-turunan 5'-deoksi-sitidina
FI960726A (fi) Bitumikoostumus
ID20144A (id) Pengaliran vertikal
NO992059D0 (no) 2-metoksyfenylpiperazinderivater
DE59706428D1 (de) Schaltungsanordnung
DE69726233D1 (de) Taktschema
DE69721912D1 (de) Anschlusselement
PT964867E (pt) Antagonistas da taquicinima
DE69633505D1 (de) Ablenksystem
BR9700954A (pt) Pigmento
DE69718354D1 (de) Papierklammer
DE59702067D1 (de) Flexible leiterbahnverbindung
BR9709521A (pt) "3-Cianoaril-pirazóis"
ATA91996A (de) Standseilbahn
FR2758444B1 (fr) Boucles d'oreille

Legal Events

Date Code Title Description
FB34 Technical and formal requirements: requirement - article 34 of industrial property law
B11T Dismissal of application maintained [chapter 11.20 patent gazette]